Quarterly report pursuant to Section 13 or 15(d)

Discontinuing Operations - Summarized results of consolidated discontinued operations (Details)

v3.20.2
Discontinuing Operations - Summarized results of consolidated discontinued operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 24, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Income Statement Information            
Revenue   $ 0 $ 428 $ 0 $ 10,066  
Cost of revenues   0 567 0 7,667  
Gross profit   0 (139) 0 2,399  
Research and development   0 47 0 937  
General and administrative   (9) 796 (83) 4,306  
Sales and marketing   0 15 1,528  
Restructuring costs   0 100 0 100  
Transaction costs   9 0 9 651  
Impairment of patents and other intangible assets   0 601 0 601  
Total operating expenses   0 1,559 (74) 8,123  
Income (loss) from discontinuing operations   0 (1,698) 74 (5,724)  
Interest expense   0 (38) 0 (2,211)  
Total other income (expense)   0 8,458 0 6,285  
Net income (loss) from discontinuing operations   0 6,760 74 561  
Current assets of discontinuing operations:            
Accounts receivable, net of allowance for doubtful accounts of $4,518 in 2020; $4,536 in 2019   0   0   $ 71
Current assets of discontinuing operations   0   0   71
Current liabilities of discontinuing operations            
Accounts payable and accrued expenses   578   578   1,137
Due to Interpace Biosciences, Inc.   0   0   92
Current liabilities of discontinuing operations   578   578   1,229
Allowance for doubtful accounts   4,518   4,518   $ 4,536
Cash Flow Information            
Income from discontinuing operations   0 6,760 74 561  
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations            
Depreciation       0 542  
Amortization       0 613  
Provision for bad debts       (28) 323  
Accounts payable settlements       (43) 0  
Stock-based compensation       (8) 91  
Amortization of operating lease right-of-use assets       0 436  
Amortization of discount of debt and debt issuance costs       0 601  
Loss on extinguishment of debt       0 328  
Interest added to Convertible Note       0 343  
Change in working capital components:            
Accounts receivable       99 711  
Other current assets       0 277  
Other non-current assets       0 2  
Accounts payable, accrued expenses and deferred revenue       (516) (1,273)  
Obligations under operating leases       0 (368)  
Due to Interpace Biosciences, Inc.       (92) 0  
Net cash used in operating activities, discontinuing operations       (514) (5,309)  
Clinical Business            
Income Statement Information            
Gain on disposal of business   0 1,222 0 1,222  
Current liabilities of discontinuing operations            
Due to Interpace Biosciences, Inc.   0 974 0 974  
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations            
Gain on disposal of business   0 (1,222) 0 (1,222)  
BioPharma Disposal            
Income Statement Information            
Interest expense $ (24)          
Gain on disposal of business   0 7,274 0 7,274  
Current assets of discontinuing operations:            
Accounts receivable, net of allowance for doubtful accounts of $4,518 in 2020; $4,536 in 2019   0 4,145 0 4,145  
Adjustments to reconcile income from discontinuing operations to net cash used in operating activities, discontinuing operations            
Amortization of operating lease right-of-use assets       0 1,969  
Gain on disposal of business   $ 0 $ (7,274) $ 0 $ (7,274)